Cargando...
Golimumab in the treatment of ulcerative colitis
Golimumab was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of moderate-to-severe ulcerative colitis in 2013 and was the third antitumour-necrosis-factor therapy after adalimumab and infliximab licensed for this indication. However, given it is t...
Gardado en:
| Publicado en: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6351715/ https://ncbi.nlm.nih.gov/pubmed/30728858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284818821266 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|